Date: 2017-03-30
Type of information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at the American Association for Cancer Research (AACR) Annual Meeting
Company: ADC Therapeutics (Switzerland)
Product: ADCT-402
Action mechanism: antibody drug conjugate. ADCT-402 is an anti-CD19 PBD-conjugate, with presented data demonstrating potent and specific in vitro and in vivo anti-tumor activity against CD19-positive hematological tumors as well as excellent tolerability.
Disease:
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest news: • On March 30, 2017, ADC Therapeutics announced that it will present a poster that highlight preclinical results from ADCT-402 at the American Association for Cancer Research (AACR) Annual Meeting 2017. The poster is titled "Characterization of the mechanism of action, pharmacodynamics and preclinical safety of ADCT-402, a pyrrolobenzodiazepine (PBD) dimer-containing Antibody Drug Conjugate (ADC) targeting CD19-expressing hematological malignancies" (Abstract #51). The data confirm the mode of action of ADCT-402 and provide relevant pharmacodynamic assays and preclinical safety assessment to guide the clinical development of this ADC in B-cell malignancies.
